Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1981 May;32(2):534–541. doi: 10.1128/iai.32.2.534-541.1981

Development of a Vaccine Against Experimental Cholera and Escherichia coli Diarrheal Disease

R S Rappaport 1, G Bonde 2
PMCID: PMC351479  PMID: 7019073

Abstract

The results of the present investigation indicate a simple approach to the development of a single-vaccine formula which may ultimately be used to confer protection against both cholera and certain types of Escherichia coli diarrheal disease in humans and domestic animals. The design of the vaccine is based on the well-documented ability of cholera antitoxin to neutralize both cholera and heat-labile E. coli enterotoxins (CT and LT, respectively) and on the ability of killed E. coli to enhance the immune response to cholera toxoid and, possibly, to conventional cholera vaccine as well. Evidence presented shows that a parenterally administered E. coli vaccine, prepared from an LT-only enterotoxigenic strain, reproducibly elevated rabbit antitoxin responses to cholera toxoid and that such responses correlated with dramatic protection against live cholera vibrios and the homologous E. coli strain in the rabbit ligated loop model of diarrheal disease. The results show also that cholera vaccine acted to suppress the rabbits' immune response to the cholera toxoid and E. coli vaccine formula, even though all three antigens combined still provided significant protection against live organism challenge. On the basis of data presently available, the vaccine formula would be composed simply of cholera toxoid and E. coli vaccine, but may also include cholera vaccine. Since it has already been established that cholera toxoid and cholera vaccine are each safe for human use, additional vaccine development would require investigation of the safety of E. coli vaccine, alone and in combination with the other components.

Full text

PDF
534

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burrows W., Musteikis G. M. Cholera infection and toxin in the rabbit ileal loop. J Infect Dis. 1966 Apr;116(2):183–190. doi: 10.1093/infdis/116.2.183. [DOI] [PubMed] [Google Scholar]
  2. Evans D. J., Jr, Evans D. G., Gorbach S. L. Production of vascular permeability factor by enterotoxigenic Escherichia coli isolated from man. Infect Immun. 1973 Nov;8(5):725–730. doi: 10.1128/iai.8.5.725-730.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Germanier R., Fürer E., Varallyay S., Inderbitzin T. M. Antigenicity of cholera toxoid in humans. J Infect Dis. 1977 Apr;135(4):512–516. doi: 10.1093/infdis/135.4.512. [DOI] [PubMed] [Google Scholar]
  4. Holmgren J., Svennerholm A. M., Lönnroth I., Fall-Persson M., Markman B., Lundbeck H. Development of improved cholera vaccine based on subunit toxoid. Nature. 1977 Oct 13;269(5629):602–604. doi: 10.1038/269602a0. [DOI] [PubMed] [Google Scholar]
  5. Honda T., Finkelstein R. A. Selection and characteristics of a Vibrio cholerae mutant lacking the A (ADP-ribosylating) portion of the cholera enterotoxin. Proc Natl Acad Sci U S A. 1979 Apr;76(4):2052–2056. doi: 10.1073/pnas.76.4.2052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Levine M. M., Hughes T. P., Young C. R., O'Donnell S., Craig J. P., Holley H. P., Bergquist E. J. Antigenicity of purified glutaraldehyde-treated cholera toxoid administered orally. Infect Immun. 1978 Jul;21(1):158–162. doi: 10.1128/iai.21.1.158-162.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Nalin D. R., al-Mahmud A., Curlin G., Ahmed A., Peterson J. Cholera toxoid boosts serum Escherichia coli antitoxin in humans. Infect Immun. 1974 Oct;10(4):747–749. doi: 10.1128/iai.10.4.747-749.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Peterson J. W. Synergistic protection against experimental cholera by immunization with cholera toxoid and vaccine. Infect Immun. 1979 Nov;26(2):528–533. doi: 10.1128/iai.26.2.528-533.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Pierce N. F. Protection against challenge with Escherichia coli heat-labile enterotoxin by immunization of rats with cholera toxin/toxoid. Infect Immun. 1977 Nov;18(2):338–341. doi: 10.1128/iai.18.2.338-341.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Rappaport R. S., Bonde G., McCann T., Rubin B. A., Tint H. Development of a purified cholera toxoid. II. Preparation of a stable, antigenic toxoid by reaction of purified toxin with glutaraldehyde. Infect Immun. 1974 Feb;9(2):304–317. doi: 10.1128/iai.9.2.304-317.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Rappaport R. S., Pierzchala W. A., Bonde G., McCann T., Rubin B. A. Development of a purified cholera toxoid. III. Refinements in purification of toxin and methods for the determination of residual somatic antigen. Infect Immun. 1976 Sep;14(3):687–693. doi: 10.1128/iai.14.3.687-693.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Svennerholm A. M., Holmgren J. Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid. Infect Immun. 1976 Mar;13(3):735–740. doi: 10.1128/iai.13.3.735-740.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES